

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
July 20, 2017**

**ORDER GRANTING CONFIDENTIAL TREATMENT  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**Artemis Therapeutics, Inc.**

**File No. 000-24431 - CF#34310**

---

Issuer, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 8-K/A filed on October 18, 2016, as amended.

Based on representations by Artemis Therapeutics, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.1                      through March 30, 2027

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Field  
Secretary